Freshfields advises Vivoryon Therapeutics on strategic regional licensing partnership with Simcere
The international law firm Freshfields Bruckhaus Deringer ('Freshfields') has advised Vivoryon Therapeutics N.V., a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines, on today's announced strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. Both companies aim to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer’s disease (AD) in Greater China.
The cooperation foresees a regional license for Simcere to develop and commercialize varoglutamstat (PQ912), Vivoryon’s Phase 2b-stage N3pE amyloid-targeting oral small molecule glutaminyl cyclase (QPCT) inhibitor with disease-modifying potential for AD, as well as the company’s preclinical monoclonal N3pE-antibody PBD-C06 in the Greater China region.
Under the terms of the agreement, Vivoryon will receive an upfront payment and will also be eligible for payments upon achievement of certain development and sales milestones, totalling altogether a value of over 565 million US dollars. In addition, Vivoryon will receive double-digit royalties on sales.
The Freshfields team, which has advised on all legal aspects comprised partner Jochen Dieselhorst and associate Elisabeth Wulf (both Corporate).
Media inquiries: Heiner Seidel, Senior Communications Lead Germany & Austria, E email@example.com T +49 69 27 30 84 25.
Notes to editors
About Freshfields Bruckhaus Deringer
Freshfields Bruckhaus Deringer LLP is a global law firm with a long track record of successfully advising the world's leading national and multinational corporations and financial institutions on ground-breaking and business-critical challenges. Our team of more than 2,800 lawyers and other legal professionals delivers global results from our 28 offices worldwide. Our commitment, local and multinational expertise and business know-how means our clients can rely on us when it matters most.